文献速递运动医学关节外科

距骨骨软骨损伤的骨髓刺激术:10年后临床结果能否维持?

Bone Marrow Stimulation for Osteochondral Lesions of the Talus: Are Clinical Outcomes Maintained 10 Years Later?
PubMed 文献 · Am J Sports Med · 2021-03-04

本研究回顾性分析202例踝(189例患者)接受关节镜下骨髓刺激术(BMS)治疗距骨骨软骨损伤(OLT)且随访至少10年的病例。结果显示疼痛和功能评分在术后1年显著改善并维持至10年以上,平均随访13.9年,20.8%的踝有大型病灶(≥150 mm²),12例踝接受翻修手术。病灶大小(术前MRI测量≥150 mm²)和肥胖(BMI≥25)是翻修手术的显著预后因素。

要点

  • BMS治疗OLT在平均13.9年随访时仍维持满意的疼痛和功能改善。
  • 病灶≥150 mm²和BMI≥25与翻修手术风险显著相关。
  • 约20.8%的踝有大型病灶,12例踝接受翻修手术。

核心结论

  • BMS治疗OLT在平均随访13.9年时获得满意的临床结果,手术成功可能取决于病灶大小和患者BMI。

研究设计与样本

  • 回顾性病例系列,证据等级4级,纳入202例踝(189例患者),接受BMS治疗OLT且随访至少10年。

主要发现

  • 疼痛VAS从术前7.11±1.73改善至术后1年1.44±1.52、3-6年1.46±1.57、≥10年1.99±1.67(P<.001)。
  • 踝-后足评分从术前58.22±13.57改善至术后1年86.88±10.61、3-6年86.17±10.23、≥10年82.76±11.65(P<.001)。
  • 末次随访FAOS:疼痛82.97±13.95,症状81.81±14.64,日常生活83.49±11.04,运动79.34±11.61,生活质量78.71±12.42。
  • 12例踝在平均53.5个月后接受翻修手术。
  • 病灶大小(术前MRI测量≥150 mm²,P=.014)和肥胖(BMI≥25,P=.009)是翻修手术的显著预后因素。

关键数值与推荐

  • 病灶大小≥150 mm²与翻修手术风险显著相关(P=.014)。
  • BMI≥25与翻修手术风险显著相关(P=.009)。

临床怎么用

  • BMS可作为OLT的一线治疗,长期随访显示临床结果维持满意。
  • 对于病灶≥150 mm²或BMI≥25的患者,应告知翻修手术风险可能增加。

局限性

  • 回顾性病例系列设计,证据等级4级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Arthroscopic bone marrow stimulation (BMS) is considered the first-line treatment for osteochondral lesions of the talus (OLTs). However, the long-term stability of the clinical success of BMS remains unclear. PURPOSE: To investigate the long-term clinical outcomes among patients who underwent BMS for OLT and to identify prognostic factors for the need for revision surgery. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: A retrospective analysis was performed on 202 ankles (189 patients) that were treated with BMS for OLT and had a minimum follow-up of 10 years. The visual analog scale for pain, American Orthopaedic Foot & Ankle Society ankle-hindfoot score, and the Foot and Ankle Outcome Score (FAOS) were assessed by repeated measures analysis of variance. Prognostic factors associated with revision surgery were evaluated with Cox proportional hazard regression models and log-rank tests. RESULTS: The mean lesion size was 105.32 mm2 (range, 19.75-322.79); 42 ankles (20.8%) had large lesions (≥150 mm2). The mean visual analog scale for pain improved from 7.11 ± 1.73 (mean ± SD) preoperatively to 1.44 ± 1.52, 1.46 ± 1.57, and 1.99 ± 1.67 at 1, 3 to 6, and ≥10 years, respectively, after BMS (P < .001). The mean ankle-hindfoot score also improved, from 58.22 ± 13.57 preoperatively to 86.88 ± 10.61, 86.17 ± 10.23, and 82.76 ± 11.65 at 1, 3 to 6, and ≥10 years after BMS (P < .001). The FAOS at the final follow-up was 82.97 ± 13.95 for pain, 81.81 ± 14.64 for symptoms, 83.49 ± 11.04 for activities of daily living, 79.34 ± 11.61 for sports, and 78.71 ± 12.42 for quality of life. Twelve ankles underwent revision surgery after a mean 53.5 months. Significant prognostic factors associated with revision surgery were the size of the lesion (preoperative magnetic resonance imaging measurement ≥150 mm2; P = .014) and obesity (body mass index ≥25; P = .009). CONCLUSION: BMS for OLT yields satisfactory clinical outcomes at a mean follow-up of 13.9 years. The success of the surgery may depend on the lesion size and body mass index of the patient.

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Park JH, Park KH, Cho JY, et al. Bone Marrow Stimulation for Osteochondral Lesions of the Talus: Are Clinical Outcomes Maintained 10 Years Later? Am J Sports Med. 2021. PMID: 33661712. doi:10.1177/0363546521992471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。